Sign in

    Crypta Devarakonda

    Research Analyst at Truist Securities

    Kripa Devarakonda is a Research Analyst at Truist Securities specializing in biotechnology and life sciences, covering companies such as Amgen Inc., Regeneron Pharmaceuticals, Incyte, Arvinas, and Biogen. She tracks the biotech sector closely, with over 340 stock ratings issued and a recent one-year success rate of 37% as measured by TipRanks, though her average return per rating has been -2.8%. Devarakonda has been with Truist Securities since at least 2021 and regularly moderates high-profile industry events and symposiums, collaborating with senior analysts. She holds a Ph.D. and is registered with FINRA, supporting her credentials as a securities professional.

    Crypta Devarakonda's questions to BRISTOL MYERS SQUIBB (BMY) leadership

    Crypta Devarakonda's questions to BRISTOL MYERS SQUIBB (BMY) leadership • Q3 2024

    Question

    Crypta Devarakonda asked about the HFpEF program, specifically how Phase II data from mavacamten translates to the new lead asset MYK-224, and inquired about the market size and development timelines.

    Answer

    Head of Global Drug Development Samit Hirawat explained the mavacamten study provided confidence to advance MYK-224, with Phase II data expected in the next couple of years and Phase III readouts in the early part of the next decade. Chief Commercialization Officer Adam Lenkowsky added that HFpEF is a significant opportunity, affecting ~3 million people in the U.S. in a market expected to nearly double by 2032.

    Ask Fintool Equity Research AI